BROOKLYN PARK, Minn., March 1, 2018 /PRNewswire/ — 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its medical device for mitral regurgitation (MR) will be highlighted in two presentations at the Cardiovascular Research Technologies (CRT) meeting held March 3-6, 2018 in Washington, DC.
4C Medical is developing the first MR treatment that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology. The novel design eliminates known issues associated with current transcatheter mitral valve replacement (TMVR) technologies which rely on placement and fixation in the native mitral annulus and left ventricle.
Jeffrey Chambers, MD will present “4C Solutions that Preserve the Native Mitral Valve” at 10:21 am Tuesday, March 6. The presentation will be held in the Omni Shoreham Hotel Blue Room as part of the CRT Valve Structural Innovations session. Dr. Chambers is the Director of the Cardiac Catheterization Lab at Metropolitan Heart and Vascular Institute in Minneapolis, MN. He is also the Founder and Chief Medical Officer of 4C Medical.
Philippe Généreux, MD will present “Innovation I: A Novel Transcatheter MR Treatment Technology” at 11:00 am Tuesday, March 6. The presentation will be held in the Omni Shoreham Hotel Hampton Ballroom as part of the CRT Cardiovascular Innovations session. Dr. Généreux is Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, NJ) and a practicing Interventional Cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada).
About 4C Medical Technologies, Inc.
4C Medical is a medical device company developing minimally invasive technologies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. The company’s implant is the first MR treatment with supra-annular positioning and atrial-only fixation. It preserves the native mitral valve and left ventricle, eliminating known issues associated with transcatheter mitral valve replacement technologies which rely on placement and fixation in the native mitral annulus and left ventricle.
Media Contacts
Robert Thatcher
Chief Executive Officer
(612) 600-8951
rthatcher@4CMed.com
Jim Flaherty
Chief Financial Officer
(612) 599-0650
jflaherty@4CMed.com
SOURCE 4C Medical Technologies, Inc.
